Life Sciences / Biotech
The intellectual property lawyers and technical specialists of the Life Sciences/Biotech Practice Group use their legal, biotechnology and life sciences skills to evaluate current technologies and provide expert advice on intellectual property strategy and business development. They have years of experience in the pharmaceutical industry, technology transfer and licensing, life sciences patents and conducting intellectual property audits and due diligence studies. In addition to providing a full range of Life Sciences patent services, our clients look to us for licensing their technology or developing internal intellectual property policies and procedures.
The practice group includes patent attorneys and technical advisors who have years of experience and expertise in biotechnology, bioinformatics, immunology, agricultural biotechnology, gene therapy, genomics, medical devices, diagnostics, pharmaceuticals, proteomics, vaccines and drug delivery.
Many of our group members hold doctorate or advanced scientific degrees in immunology, biochemistry, botany, biotechnology and molecular biology. Many have worked as examiners at the United States Patent and Trademark Office (USPTO) or have held various positions in industry as researchers or in-house counsel.
We understand the complex USPTO procedures, as well as the scientific and business issues. This is what makes the difference for you. BSKB provides uniquely insightful technical advice and intellectual property legal counsel to a growing list of clients who enjoy the benefits of that added value.
Attorneys and Professionals
October 11, 2022
World IP Review
Dr. Hailey Bureau was recently published in World IP Review’s latest digital edition of World IP Review.
July 1, 2022
BSKB's Hailey R. Bureau, Ph.D., was quoted in an article for Bloomberg Law regarding recent rulings by the US Court of Appeals for the Federal Circuit regarding strict enforcement of certain Patent Act provisions. These rulings regarding Section 112(a), a written description requirement and an enablement standard, have created a high burden for Applicants in the life science industry to overcome.
October 19, 2022
For those who have filed or will file trademark applications in the USPTO, we wish to inform you of an important update from the USPTO regarding Office Action response deadlines.
October 14, 2022
Our previous announcement of November 24, 2021 noted that the U.S. Patent and Trademark Office (USPTO) delayed implementation of the non-DOCX filing surcharge until January 1, 2023. The USPTO has not announced whether there is a need to delay implementation beyond January 1, 2023.